Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme
DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.
Dr Strub-Wourgaft has been a pillar of scientific expertise at DNDi for the last nine years, bringing strong medical and scientific credibility to the organization in R&D clinical development. As the Medical Director, she developed and strengthened the capacity and expertise of DNDi in Regulatory Affairs, Pharmacovigilance and Quality Assurance. She played an active role in promoting mycetoma as the 18th NTD in the WHO list. Her team’s latest achievement was overseeing the clinical development and dossier preparation for fexinidazole, the first oral treatment for African sleeping sickness, which was submitted by industrial partner Sanofi to the European Medicines Agency for review in January of this year.
Dr Strub-Wourgaft came to DNDi in 2009 with more than 15 years of clinical development experience, including as Director, Clinical Development at Trophos, Medical Director for the French office of Aspreva, and several years at each of Pfizer and Lundbeck. Dr Strub-Wourgaft earned her MD at Necker Hospital, Université René Descartes in Paris in 1983.
In her new role, Dr Strub-Wourgaft will provide strategic leadership and direct oversight of DNDi’s five NTD teams, which are working to deliver new and improved treatment regimens for human African trypanosomiasis, leishmaniasis, Chagas disease, filarial diseases, and mycetoma.
Photo credit: Neil Brandvold-DNDi
